Malaria, Plasmodium Falciparum
Conditions
Keywords
Malaria, Plasmodium falciparum, RH5
Brief summary
The purpose of this study is to assess two new malaria vaccines, ChAd63 RH5 and MVA RH5, at different doses and alone or in combination. The study will enable us to assess the safety of the vaccines and the extent of the immune response in healthy volunteers. We will do this by giving volunteers one or two vaccinations, doing blood tests and collecting information about any symptoms that occur after vaccination. This is the first trial to use these vaccines in humans.
Interventions
BIOLOGICALChAd63 RH5 low dose
ChAd63 RH5 at 5 x 10\^9 vp
BIOLOGICALChAd63 RH5 full dose
ChAd63 RH5 at 5 x 10\^10 vp
BIOLOGICALMVA RH5 low dose
MVA RH5 at 1 x 10\^8 pfu
BIOLOGICALMVA RH5 full dose
MVA RH5 at 2 x 10\^8 pfu
Sponsors
European Commission
University of Oxford
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adults aged 18 to 50 years * Able and willing (in the Investigator's opinion) to comply with all study requirements * Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner * For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day(s) of screening and vaccination * Agreement to refrain from blood donation during the course of the study * Provide written informed consent
Exclusion criteria
* Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period * Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data. * Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate * Any confirmed or suspected immunosuppressive or immunodeficient state, including human immunodeficiency virus (HIV) infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed) * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products. * Any history of anaphylaxis in reaction to vaccination * Pregnancy, lactation or willingness/intention to become pregnant during the study * History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ) * History of serious psychiatric condition * Any other serious chronic illness requiring hospital specialist supervision * Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week * Suspected or known injecting drug abuse in the 5 years preceding enrolment * Seropositive for hepatitis B surface antigen (HBsAg) * Seropositive for hepatitis C virus (antibodies to HCV) * History of clinical malaria (any species) * Travel to a malaria endemic region during the study period or within the previous six months * Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis * Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data * Inability of the study team to contact the volunteer's general practitioner (GP) to confirm medical history and safety to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess the safety of ChAd63 RH5 when administered alone and in heterologous prime-boost with MVA RH5 | 240 days | Occurrence of solicited and unsolicited adverse events will be monitored at each clinic visit from diary cards, clinical review, clinical examination (including observations) and laboratory results. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess the cellular and humoral immunogenicity of ChAd63 RH5 when administered alone, and in heterologous prime-boost with MVA RH5 in healthy volunteers. | 240 days | P. falciparum RH5-specific immunogenicity will be assessed by a variety of immunological assays. These may include ex vivo ELISpot assays for interferon gamma and flow cytometry assays, as well as antibody ELISAs, functional antibody assays and B cell analyses. Other exploratory immunological assays including cytokine analysis, other antibody assays, anti-adenovirus antibodies, DNA analysis of genetic polymorphisms potentially relevant to vaccine immunogenicity and gene expression studies amongst others may be performed at the discretion of the Investigators. |
Countries
United Kingdom
Outcome results
None listed